Cited by 85Alzheimer's disease research and treatmentsNeurogenesis and neuroplasticity mechanismsNeuroscience and Neuropharmacology Research

Regulation of ApoE receptor proteolysis by ligand binding

Hoe, Hyang-Sook, Rebeck, G. William·2005·Molecular Brain Research

Abstract

Two brain receptors for apolipoprotein E (apoE), the apoE receptor 2 (apoEr2) and the very low density lipoprotein receptor (VLDLr), are important in neuronal migration during development. Using a series of tagged constructs, we found that these two receptors undergo extracellular cleavages to release secreted forms of the receptors and intramembranous cleavages to degrade the C-terminal fragments. Release of the extracellular domains was blocked by an inhibitor of metalloproteinases and increased by PMA. Accumulation of the intracellular domain was increased by the presence of an inhibitor of gamma-secretase. ApoE binding to these receptors caused increased release of the extracellular domain and accumulation of the intracellular domains; similar increases in receptor proteolytic domains were observed from endogenous apoEr2 after treatment of primary neurons or rat hippocampus with an apoE-derived peptide. The human apoE isoforms promoted proteolysis to different degrees, with apoE2 resulting in a greater accumulation of the C-terminal fragments of apoEr2 compared with apoE4. These effects of apoE on receptor proteolysis were mediated by the ligand binding domain of the receptor. Similar promotion of receptor cleavage was seen with two other ligands, reelin and activated alpha2-macroglobulin. We suggest that signaling promoted by these receptors depends in part on these regulated proteolytic events.

Integrity signals

Registry

Crossref · 10.1016/j.molbrainres.2005.02.013

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • DAPT treatment increases ApoER2 CTFs, indicating that γ-secretase is responsible for ApoER2-CTF processing to produce the corresponding intracellular domain (ICD).

    “When ApoER2-expressing cells are treated with DAPT, a γ–secretase inhibitor, the amount of CTFs increase [39], [40], indicating that γ–secretase is responsible for the ApoER2-CTF processing to produce the corresponding intracellular domain (ICD).”
  • Overexpressing adaptor proteins associated with higher cell surface receptor levels also increases the ApoER2 CTF level.

    “When over expressing adaptor proteins, which are associated with higher levels of receptor at the cell surface, the ApoER2 CTF (the product of sheddases and substrate of the γ-secretase complex) is also detected at a higher level [40], [54].”

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Hoe, H.-S., & Rebeck, G. W.
Affiliations
Georgetown University (US)
Corresponding author
Rebeck, G. William
Venue
Molecular Brain Research
Publisher
Elsevier BV
Published
2005-06
Volume
137
Issue
1-2
Pages
31-39
ISSN
0169-328X (ISSN-L)
OpenAlex
W2059011964
Cited by
85
References
4
Citations by year
2026: 1 · 2025: 1 · 2024: 1 · 2023: 3 · 2022: 1 · 2021: 1 · 2020: 2 · 2019: 2 · 2018: 4 · 2017: 4 · 2016: 5 · 2015: 2 · 2014: 4 · 2013: 3 · 2012: 3
FWCI
5.10
Type
journal article
Language
en
Open access
closed
Locations
  • Molecular Brain Research (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health
  • National Institute on Aging (AG14473)
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Life Sciences › Neuroscience › Developmental Neuroscience › Neurogenesis and neuroplasticity mechanisms
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
Keywords
apolipoprotein E, VLDLR, receptor proteolysis, ligand binding, metalloproteinase cleavage, gamma-secretase, C-terminal fragment, APOE isoforms, reelin, alpha2-macroglobulin, neuronal migration, hippocampus, primary neurons
MeSH terms
Reelin Protein, Animals, Apolipoproteins E, Binding Sites, Binding, Competitive, Cell Membrane, Chlorocebus aethiops, Enzyme Inhibitors, Hippocampus, Humans, Ligands, Male, Peptide Hydrolases, Endopeptidases, Peptides, Protein Binding, Receptors, LDL, Aspartic Acid Endopeptidases, Rats, Sprague-Dawley, Protein Structure, Tertiary, Receptors, Lipoprotein, COS Cells, LDL-Receptor Related Proteins, Rats, Apolipoprotein E4, Apolipoprotein E2, Amyloid Precursor Protein Secretases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review